JAK2 and myeloproliferative disorder: The JAK2 p.V617F mutation, typically associated with myeloproliferative neoplasms, has been increasingly recognized in solid tumors (Jeong et al., 2008) and may mediate immune evasion, inflammation-driven metastasis, and niche adaptation (Wolf et al., 2012; Wu et al., 2017; Looyenga et al., 2012).